The study, led by Alexis Carriere and Stephane Legriel of the Centre Hospitalier de Versailles together with a broad network of French intensivists, set out to answer a deceptively simple question: does fever developing within the first 24 hours after the onset of convulsive status epilepticus independently worsen neurological recovery? To find out, the researchers turned to the ICTAL Registry, a prospective, multicenter observational database that has become one of the richest sources of real-world evidence on this devastating neurological emergency. Their analysis encompassed 952 adults admitted to 23 French intensive care units, making it one of the largest efforts to date to disentangle the prognostic meaning of hyperthermia in this population.

The technical definition matters here. Fever was defined as a core temperature of at least 38 degrees Celsius, measured during the first 24 hours following seizure onset. The outcome of interest was equally concrete: a favorable neurological outcome at 90 days, operationalized as a score of 4 or 5 on the Glasgow Outcome Scale, which ranges from death and persistent vegetative states at the bottom to good recovery and moderate disability with independence at the top. This 90-day functional endpoint is widely regarded as the gold standard in neurocritical care trials because it captures what actually matters to patients and families—whether a person can think, move, and live independently after a catastrophic brain event.

What the team found was striking in its prevalence. Of the 952 patients, 382—41.2 percent—developed fever within the first 24 hours of their intensive care stay. That figure alone underscores how common this physiological disturbance is in the immediate aftermath of prolonged convulsive seizures. But the origins of that fever proved to be decidedly multifactorial. Some patients had infectious causes directly related to the status epilepticus itself, including systemic infections or infections of the central nervous system such as encephalitis or meningitis. Others developed early aspiration pneumonia, a well-known complication when consciousness is lost and airway protective reflexes fail. And a third contributor emerged that is less obvious to outsiders: the sheer intensity of the convulsive activity, which generates massive heat and triggers inflammatory cascades throughout the body.

To isolate which of these factors truly drove fever, the investigators employed sophisticated statistical machinery, including multivariable logistic regression and matching techniques designed to balance the fever and non-fever groups on measurable characteristics. After matching, a revealing pattern emerged: only the intensity of convulsive activity remained associated with the occurrence of fever. In other words, the harder and longer the brain seized, the more likely the body was to run hot. The infectious contributors, while clinically important in their own right, did not stand out as independent drivers of early fever once the analysis accounted for other variables—a finding that reframes early hyperthermia in status epilepticus as a signal of seizure severity rather than a standalone disease process.

The prognostic verdict, however, was the study’s headline result. In multivariable analyses adjusting for the full panel of potential confounders, early fever was not independently associated with 90-day functional outcome. Instead, the familiar determinants of recovery reasserted themselves. Patients younger than 60 years and those with a Charlson Comorbidity Index below 3—indicating a lighter burden of chronic illness—had significantly better odds of favorable neurological outcome. Conversely, two factors predicted poor recovery: when the underlying cause of the status epilepticus was a cerebral insult, such as a stroke or other structural brain injury, and when the episode proved refractory, meaning seizures persisted despite adequate doses of first- and second-line anticonvulsant drugs. These predictors align with decades of literature on status epilepticus outcomes, reinforcing that etiology, age, comorbidity, and treatment resistance remain the pillars of prognosis.

The biological backdrop to this question is worth unpacking. In many acute brain injuries, fever is genuinely harmful: elevated brain temperature accelerates excitotoxic neurotransmitter release, worsens metabolic supply-demand mismatch, promotes blood-brain barrier breakdown, and amplifies inflammatory signaling. Consensus guidelines for intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke accordingly recommend aggressive temperature control. Experimental work in epilepsy has also shown that inflammatory mediators such as cytokines can lower seizure thresholds and perpetuate epileptic activity, creating a plausible loop in which fever and seizures feed each other. It was precisely this mechanistic plausibility that made the ICTAL findings surprising—and important. If fever in status epilepticus were an independent toxin, one would expect it to survive statistical adjustment. It did not.

The authors are careful, appropriately, not to overclaim. Their conclusions note that early fever is highly prevalent and appears to reflect seizure intensity rather than overall disease severity, that it showed no independent association with 90-day neurological outcome, and that no major prognostic impact is suggested—although they explicitly acknowledge that a modest association cannot be excluded. This caution is scientifically warranted. An observational registry, however large and well-adjusted, cannot fully eliminate confounding by indication: patients who seize violently enough to become febrile are also patients whose illness is intrinsically more severe, and no statistical model can perfectly separate the heat from the fire. The researchers also stress that their findings do not permit conclusions about whether actively cooling patients—targeted temperature management—would help or harm in status epilepticus. That question was tested in a previous randomized trial by the same group, published in the New England Journal of Medicine in 2016, which found that induced hypothermia did not improve outcomes in convulsive status epilepticus, and the current results neither revive nor bury the idea of temperature intervention.

For clinicians at the bedside, the practical message is nuanced but actionable. A fever in the first day of status epilepticus should still trigger a diligent hunt for its cause—blood cultures, chest imaging, lumbar puncture when infection of the central nervous system is suspected—because treatable infections matter regardless of whether the fever itself is prognostically neutral. Aspiration pneumonia, in particular, demands vigilance and early antibiotic therapy. But the new evidence suggests that the number on the thermometer, in isolation, should not be read as a sentence on the patient’s future. The stronger prognostic signals remain the ones clinicians already know: the patient’s age, their chronic health burden, the cause of the seizures, and whether the seizures yield to treatment.

For the field of neurocritical care, the study exemplifies the value of large, prospective, disease-specific registries. The ICTAL Registry, registered with ClinicalTrials.gov and coordinated through the IctalGroup Research Network based at Versailles, has previously yielded insights ranging from early electrocardiographic changes in status epilepticus to health-related quality of life in survivors. By demonstrating that one of the most feared secondary brain insults may be a marker rather than a mechanism of poor outcome in this specific condition, the current analysis sharpens the research agenda: future work should focus on modulating seizure intensity itself and on rigorously testing temperature-control strategies in properly designed trials, rather than assuming that fever behaves identically across all forms of acute brain injury. In medicine, as this study elegantly shows, even the most intuitive assumptions deserve to be tested against data.

Subject of Research: The prognostic significance of early fever in adult convulsive status epilepticus

Article Title: Prognostic Significance of Early Fever in Convulsive Status Epilepticus: Insights from the ICTAL Registry

Article References: Carriere, A., Chelly, J., Quenot, J.-P., Lascarrou, J.-B., Bernard, C., Lesieur, O., Monchi, M., Beuret, P., Sigaud, F., Sboui, G., Bailly, P., Chambon, R., Fontaine, C., Mongardon, N., Cerf, C., Bruel, C., Pichon, N., Argaud, L., Desmeulles, I., … Legriel, S. (2026). Prognostic Significance of Early Fever in Convulsive Status Epilepticus: Insights from the ICTAL Registry. Neurocritical Care. https://doi.org/10.1007/s12028-026-02673-2

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02673-2

Keywords: status epilepticus, fever, hyperthermia, ICTAL Registry, neurocritical care, intensive care, prognosis, seizures, secondary brain injury, Glasgow Outcome Scale, temperature management, epilepsy

The study, published in Epigenetics Communications, took advantage of a rare and precious resource: cerebrospinal fluid, the clear liquid that bathes the brain and spinal cord, collected day after day from patients fighting for their lives in a neurovascular intensive care unit. Because cerebrospinal fluid is drained as part of routine clinical management to relieve pressure inside the skull after a hemorrhage, the researchers could sample a tissue that sits in intimate contact with the injured brain — something that blood tests simply cannot offer. From 260 patients, they generated longitudinal, genome-wide DNA methylation data spanning 13 days after the bleed, then validated their findings in an independent group of 100 patients.

DNA methylation is a chemical modification in which small methyl groups are attached to specific positions in the DNA sequence, typically dampening the activity of nearby genes. It is a master regulator of how the same genetic blueprint produces neurons, immune cells, and everything else in the body, and it is known to influence brain function, plasticity, and recovery after injury. The Pittsburgh team focused on 36 candidate genes involved in iron homeostasis, the body’s system for managing iron — a logical target because a ruptured aneurysm dumps hemoglobin-rich blood into the cerebrospinal fluid, where heme is broken down to release free, unbound ferrous iron. That free iron is dangerous: it fuels a distinctive form of iron-dependent cell death called ferroptosis, which has been implicated in secondary brain injury after hemorrhagic stroke in animal models.

To make sense of the longitudinal data, the researchers employed group-based trajectory analysis, an unsupervised clustering method that sorts patients into groups sharing similar patterns of change over time. Rather than estimating a single average trajectory for the whole sample, the technique asks whether the population is actually composed of distinct subgroups, each with its own methylation course. Crucially, the team automated the modeling procedure with a predefined decision tree, removing the subjective, iterative choices that traditionally plague this kind of analysis. Of 637 methylation sites examined across the candidate genes, 183 sites in 33 genes yielded reliable trajectory groups and were carried forward for association testing against patient outcomes.

One site towered above the rest: cg25713625, a methylation position within the STEAP3 gene, which encodes a metalloreductase responsible for converting stable, insoluble ferric iron into its more reactive, soluble ferrous form. In the discovery sample, patients whose methylation at this site fell into the highest trajectory group faced dramatically worse odds than those in the lowest group. The odds of an unfavorable outcome on the Glasgow Outcome Scale — a measure of functional recovery — were 11.7 times higher at three months and 15.6 times higher at twelve months. The odds of death were 19.1 times higher at three months and 12.8 times higher at twelve months, all meeting the study’s empirical thresholds for statistical significance.

What makes these findings compelling is that they replicated. In the independent sample of 100 patients, the same trajectory structure emerged, and the associations held: an 8.2-fold increase in odds of unfavorable recovery at three months, a 6.3-fold increase at twelve months, and a 2.3-fold increase in the odds of death at three months, with a suggestive association for death at twelve months. The effect was additive — with each step up in methylation trajectory group, the proportion of patients with poor outcomes climbed steeply. In the replication sample, not a single patient in the lowest methylation group had an unfavorable Glasgow Outcome Scale score at three months, compared with 61.5 percent of those in the highest group.

Biologically, the result makes unsettling sense. STEAP3 is essential for normal iron handling — its deficiency causes microcytic anemia with iron overload — but in the aftermath of a hemorrhage, its activity may become a liability. By converting ferric iron to the ferrous form, STEAP3 potentially increases the pool of reactive iron available to drive lipid peroxidation, the oxidative destruction of cell membranes that lies at the heart of ferroptosis. Animal studies support this logic: elevated iron after experimental subarachnoid hemorrhage raises lipid peroxide levels, and ferrostatin-1, a lipophilic antioxidant that shields membranes from lipid oxidation, reduces free iron and prevents both ferroptosis and early brain injury in those models. STEAP3 has also been linked to p53-mediated apoptosis and to immune function, and it is the only member of the STEAP family highly expressed in macrophages. Intriguingly, previous work found STEAP3 to be more than 2.5-fold overexpressed in the walls of unruptured intracranial aneurysms compared with control artery tissue.

Two other candidate genes told a more cautionary tale. A methylation site in the amyloid precursor protein gene, APP, which participates in iron efflux by stabilizing ferritin and ferroportin, showed promising associations with favorable outcomes and survival in the discovery phase, but the trajectory structure failed to replicate. A dynamic site in the inflammatory cytokine gene TNF, which sits within a hotspot of outcome-associated methylation positions, also failed replication. Only the STEAP3 signal survived independent testing, underscoring how easily early findings in epigenetic studies can dissolve under scrutiny — and how valuable embedded replication is for distinguishing robust signals from statistical noise.

Perhaps the most clinically surprising observation was that methylation at the STEAP3 site barely changed over the 13-day monitoring window. The trajectories were largely flat, suggesting that a single early measurement might capture the same predictive information as repeated sampling. Post hoc cross-sectional analyses confirmed persistent associations between continuous methylation levels and long-term outcomes at multiple time points from days 3 through 11 after the hemorrhage. The association also survived adjustment for cell type heterogeneity — the shifting mixture of blood, brain, and vessel cells that contaminates cerebrospinal fluid after a bleed — which strengthens the case that the signal reflects genuine biology rather than changing cellular composition. One caveat: methylation at the site showed only a small to moderate correlation between blood and cerebrospinal fluid, indicating that a simple blood test would likely not substitute for the brain-proximal fluid.

The researchers are careful to frame this as a first step rather than a finished clinical tool. The study population was predominantly composed of participants who self-identified as White, limiting generalizability, and the candidate gene approach, though rigorously corrected for multiple testing, may have missed signals in genes that could not be reliably modeled, including two iron homeostasis genes on the X chromosome that were excluded during quality control. Functional studies are needed to determine whether methylation at cg25713625 actually alters STEAP3 activity and ferroptosis in the injured brain, or whether it merely marks some deeper vulnerability. Still, the prospect is tantalizing: a methylation marker measurable in fluid already being drained from patients could one day help clinicians identify, within days of a devastating hemorrhage, who needs the most aggressive monitoring — and it could spotlight iron metabolism, and ferroptosis in particular, as a target for therapies that might finally move the needle on outcomes in this brutal disease.

Subject of Research: DNA methylation of the iron homeostasis gene STEAP3 in cerebrospinal fluid as a predictor of outcomes after aneurysmal subarachnoid hemorrhage

Article Title: Iron homeostasis pathway DNA methylation trajectories reveal a role for STEAP3 metalloreductase in patient outcomes after aneurysmal subarachnoid hemorrhage

Article References: Heinsberg, L. W., Weeks, D. E., Alexander, S. A., Minster, R. L., Sherwood, P. R., Poloyac, S. M., Deslouches, S., Crago, E. A., & Conley, Y. P. (2021). Iron homeostasis pathway DNA methylation trajectories reveal a role for STEAP3 metalloreductase in patient outcomes after aneurysmal subarachnoid hemorrhage. Epigenetics Communications, 1(1), Article 4. https://doi.org/10.1186/s43682-021-00003-5

Image Credits: AI Generated

DOI: 10.1186/s43682-021-00003-5

Keywords: aneurysmal subarachnoid hemorrhage, DNA methylation, STEAP3, iron homeostasis, ferroptosis, cerebrospinal fluid, epigenetics, biomarker, stroke, group-based trajectory analysis, lipid peroxidation, Glasgow Outcome Scale

The tool in question is the FUNC score, short for the Functional Outcome in Patients with Primary Intracerebral Hemorrhage score, developed by neurologists at Massachusetts General Hospital and first published in the journal Stroke in 2008. The score distills a handful of variables available at hospital admission — the volume and location of the bleed on initial imaging, the patient’s age, the Glasgow Coma Scale score on arrival, and whether the patient was already taking an anticoagulant medication such as warfarin — into a single number ranging from zero to eleven. In its original validation, the score predicted whether patients would achieve functional independence, defined as a Glasgow Outcome Scale score of four or higher, ninety days after the hemorrhage. That three-month window, however, has increasingly been recognized as an arbitrary snapshot of what is often a much longer recovery.

Recovery after brain injury is not a fixed event but a moving target. Emerging evidence, including a growing body of work on recovery trajectories after intracerebral hemorrhage, shows that many patients continue to improve between three and twelve months after the bleed. In some cohorts, a meaningful proportion of survivors who were dependent at three months walk, feed themselves, and manage their own affairs a year later. If clinicians base early prognostic conversations only on tools validated at three months, they risk anchoring families to an overly pessimistic view — or, conversely, they may lack the statistical justification to make confident statements about long-term independence at all. Recognizing this gap, a team led by Joel Neves Briard, a postdoctoral researcher in Columbia’s Department of Neurology, and senior author Jan Claassen, professor of neurology and critical care specialist, set out to ask whether the FUNC score could be stretched, without distortion, to a twelve-month horizon.

The team conducted a single-center prospective cohort study, enrolling adult patients admitted with primary intracerebral hemorrhage between February 2009 and January 2018. Prospective enrollment matters in this kind of research: rather than reconstructing cases from medical records after the fact, investigators collected structured data on patients as they arrived and followed them forward, reducing the bias and missingness that plague retrospective analyses. All patients included in the analysis had a primary hemorrhage — meaning the bleed was not secondary to trauma, aneurysm rupture, or vascular malformation — and each patient’s FUNC score was calculated at admission using the same variables that have anchored the score since its debut. Twelve months later, surviving patients’ functional status was assessed using the Glasgow Outcome Scale, a five-point measure that ranges from death to good recovery and that classifies patients scoring four or five as broadly independent.

The cohort ultimately comprised 535 patients, a substantial sample for this disease. The patients were, on average, seriously ill: their median age was 68 years, 44 percent were women, and the median National Institutes of Health Stroke Scale score at presentation was 16, a level indicating moderate to severe neurological impairment. Median FUNC score in the cohort was 8 on the eleven-point scale. Among the 445 patients with a known Glasgow Outcome Scale assessment at twelve months, 99 — roughly 22 percent — had achieved functional independence. That figure alone carries a message for families: even in a cohort skewing severely ill, more than one in five patients was living independently a year after a brain bleed, a reminder that early appearances can mislead.

The statistical heart of the study lay in testing whether the FUNC score’s predictions still held at one year. The researchers used logistic regression to calculate the area under the receiver operating characteristic curve, or AUC, the standard gauge of a prediction model’s ability to separate those who will experience an outcome from those who will not. An AUC of 0.5 indicates performance no better than a coin flip, while 1.0 represents perfect discrimination. For twelve-month functional independence, the FUNC score achieved an AUC of 0.79, with a 95 percent confidence interval of 0.75 to 0.84 — a level of discrimination broadly comparable to the score’s originally validated three-month performance. In practical terms, the score’s simple admission-time arithmetic remained nearly as informative about the one-year future as about the three-month one.

Discrimination, however, is only half the story. A model can rank patients correctly yet still misjudge how likely the outcome actually is, which is why the researchers also evaluated calibration — the agreement between predicted probabilities and observed frequencies — using a calibration plot, alongside the Brier score, a composite measure of both discrimination and calibration that penalizes confident wrong answers. The calibration plot showed reasonable agreement between predicted and observed outcomes across the probability range, with modest evidence that the score slightly overestimated the likelihood of independence at the low end of predicted probabilities. The Brier score came in at 0.15, a respectable figure for a binary clinical outcome. To address the patients lost to follow-up, the team handled missing twelve-month outcomes using multiple imputation by chained equations, a modern statistical technique that fills gaps by modeling each incomplete variable conditional on all others, preserving uncertainty rather than pretending missing data do not exist.

Finally, the investigators asked a question that has become central to the modern evaluation of clinical prediction tools: does the score actually help make decisions? Using decision curve analysis, a method developed by Vickers and Elkin that quantifies the net clinical benefit of acting on a model’s predictions across a range of risk thresholds, the team found that the FUNC score delivered measurable net benefit across threshold probabilities from 5 to 50 percent. In other words, within the range of probabilities most relevant to real clinical conversations, basing decisions on the score beat both the strategy of assuming every patient will be independent and the strategy of assuming none will be — the two extremes any prognostic tool must outperform to be worth the bedside clinician’s attention.

The implications reach beyond the family meeting. The authors point to two principal applications. The first is counseling: armed with a validated twelve-month prediction, clinicians can offer families a more honest account of long-term prospects, tempering the nihilism that has historically shadowed intracerebral hemorrhage care. This matters because premature withdrawal of life-sustaining therapy, driven in part by excessively pessimistic early prognostication, remains a documented concern in hemorrhagic stroke, and formal guidelines for neuroprognostication in critically ill adults with intracerebral hemorrhage explicitly caution against self-fulfilling prophecies. The second application is methodological. The FUNC score can support sliding dichotomy, a trial-design strategy in which the outcome threshold for success is adjusted to each patient’s predicted baseline risk — an approach pioneered in traumatic brain injury research that increases statistical power by recognizing that a modest recovery for the sickest patients may be as meaningful as a full recovery for the mildest ones.

The researchers are careful about limits. This was a single-center study at a major academic medical center, and prediction models notoriously lose calibration when transplanted to different populations and care environments; external validation across centers is needed before the twelve-month FUNC score becomes standard practice. The field’s own reporting standards, codified in the TRIPOD+AI statement for clinical prediction models, demand exactly this kind of transparency about performance, calibration, and intended use. Still, the study’s message is striking in its simplicity. A tool invented nearly two decades ago, computed from five variables a clinician can gather before the patient has even reached the intensive care unit, appears to hold its predictive power across the full year in which the brain does its slow, stubborn work of healing. For the families sitting in hospital corridors, that is not just a statistical achievement — it is a reason to keep asking the question, and to keep hoping the answer changes.

Subject of Research: Prediction of 12-month functional independence after primary intracerebral hemorrhage using the FUNC score

Article Title: Extension of the FUNC Score for Prediction of 12-Month Functional Independence after Primary Intracerebral Hemorrhage

Article References: Extension of the FUNC Score for Prediction of 12-Month Functional Independence after Primary Intracerebral Hemorrhage. (n.d.). https://doi.org/10.1007/s12028-026-02661-6

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02661-6

Keywords: intracerebral hemorrhage, stroke, FUNC score, prognostication, functional outcome, Glasgow Outcome Scale, neurocritical care, prediction model, recovery, brain bleed, Extension, FUNC